viking therapeutics - Search News

Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

The Motley Fool on MSN · 1d

Has the Bubble Burst for Viking Therapeutics Stock?

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's rapidly declining valuation be a sign that the bubble has burst for it, given its inflated price, or is the healthcare stock due for a big rally this year?

MarketWatch on MSN · 17d

What’s next for hot biotech stock Viking Therapeutics? Here’s how the company can scale up.

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed partner.

Seeking Alpha on MSN · 5h

Viking Therapeutics started at neutral by Citi

Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The investment bank said that while the drug could show superior efficacy to available options,

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics price target lowered to $70 from $120 at Maxim

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

1don MSN

Viking Therapeutics, Inc. (VKTX): One of January’s Biggest Losers

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials

Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 ...

Viking stock slides 8% following Q4 report, pipeline update

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

The Pharma Letter23h

Viking sails ahead with pivotal trial and billion dollar cash pile

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics